ALIPZA Film Coated Tablet 4 Base Milligrams
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
20-03-2023
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
PITAVASTATIN CALCIUM
Available from:
Kowa Pharmaceutical Europe Co. Ltd
Dosage:
4 Base Milligrams
Pharmaceutical form:
Film Coated Tablet
Authorization date:
2010-11-05
Summary of Product characteristics
License
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
Alipza 4mg film-coated tablets.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film coated tablet contains pitavastatin calcium equivalent to 4mg pitavastatin.
Excipient(s) include 252.34mg Lactose monohydrate.
For a full list of excipients see Section 6.1.
3 PHARMACEUTICAL FORM
Film-coated tablet.
Round white film-coated tablets embossed ‘KC’ on one face and ‘4’on the reverse.
4 CLINICAL PARTICULARS
4.1 Therapeutic Indications
Alipza is indicated for the reduction of elevated total cholesterol (TC) and LDL-C, in adult patients with primary
hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, and combined (mixed) dyslipidaemia,
when response to diet and other non-pharmacological measures is inadequate.
4.2 Posology and method of administration
For oral use only and should be swallowed whole. Alipza can be taken at any time of the day with or without food. It is
desirable that the patient takes the tablet at the same time each day. Statin therapy is generally more effective in the
evening due to the circadian rhythm of lipid metabolism. Patients should be on a cholesterol lowering diet before
treatment. It is important th
Read the complete document
